{"entity":{"id":"tak-928","kind":"drug","name":"TAK-928","aka":[],"tldr":"TAK-928 is an experimental bispecific antibody from Takeda in phase 3 trials for non-small-cell lung cancer, aimed at PD-1 and CD25 (IL-2 receptor alpha).","summary":"TAK-928 is a bispecific antibody developed by Takeda. Its targets are PD-1 and CD25 (IL-2 receptor alpha) (the sponsor names PD-1 x IL-2 receptor (CD25)). The sponsor states: Described as a first-in-class bispecific monoclonal antibody comprised of an IL-2 mutein fused with a recombinant anti-PD-1 antibody, intended to simultaneously block PD-(L)1 signalling and deliver IL-2 stimulation to tumour-specific CD8+ T cells co-expressing PD-1 and CD25, to reverse T-cell exhaustion. ClinicalTrials.gov describes the intervention as: TAK-928 will be administered by IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07217301 (A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT07217301, plans to enrol 600 participants with primary completion expected 2028-11-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TAK-928","url":"https://clinicaltrials.gov/search?intr=TAK-928"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["pd1","cd25"],"drugs":[],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07217301"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody","mechanism":"Described as a first-in-class bispecific monoclonal antibody comprised of an IL-2 mutein fused with a recombinant anti-PD-1 antibody, intended to simultaneously block PD-(L)1 signalling and deliver IL-2 stimulation to tumour-specific CD8+ T cells co-expressing PD-1 and CD25, to reverse T-cell exhaustion.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tak-928/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}],"trial":[{"id":"nct07217301","kind":"trial","name":"A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct07217301/"}]}}